2019
30 August, 2019
Interim Report For FluoGuide, Second Quarter 2019
Andreas Kjær, responsible for research of FluoGuide comments: "I am very pleased that promising data on the benefit of FG001...
FG001 is initially focused on guiding glioblastoma surgery but has potential in several other cancer indications. One of these indications...
12 August, 2019
FG001 again demonstrates strong data in guiding glioblastoma surgery – accepted for presentation at the World Molecular Imaging Congress 2019
FG001 is the first product from FluoGuide, which lights up the cancer and its invasive growth into the surrounding tissue. It helps...
3 July, 2019
FluoGuide’s ownership to key patent registered
FluoGuide’s first product FG001 lights up the cancer and its invasive growth into the surrounding tissue. FG001 is expected to...
31 May, 2019
Interim Report First Quarter 2019 for FluoGuide
Morten Albrechtsen, CEO of FluoGuide, comments: “Not even a month has passed since FluoGuide’s very successful IPO and...
Ahead of the listing at Spotlight Stock Market, FluoGuide has conducted a successful IPO which has provided the company approx. DKK...
17 April, 2019
FluoGuide’s IPO significantly oversubscribed
The subscription period expired on 15 April 2019, for FluoGuide’s unit issue of initially approx. DKK 15.9 million (incl. compensatory...
Subscription period: April 1st – April 15th, 2019. Subscription price: DKK 14.85 per unit. One (1) unit consists of three (3)...